RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the treatment of breast cancer and gastric cancer with HER2 amplification or overexpression. In colorectal cancer, HER2 as a target has also been focused in recent years.
Colorectal Cancer
DRUG: Anti-HER2 ADC
Safety, Safety was assessed by evaluation of AEs and serious AEs according to CTCAE 5.0, 1 year|Feasibility, Feasibility was determined based on any treatment -related AEs leading to delays over 15 days or discontinous of treatment., 1 year
Objective response rate, The percentage of subjects with Complete Response (CR) and Partial Response (PR)., 1 year|disease control rate,DCR, The percentage of subjects with total number of Complete Response (CR), Partial Response (PR) and stable disease (SD)., 1 year|Progression-free survival (PFS), The PFS is defined as the time from the start of treatment to the date of first documented PD or death as a result of any cause, whichever occurred first., 1 year|Overall Survival (OS), OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact., 2 year
As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the treatment of breast cancer and gastric cancer with HER2 amplification or overexpression. In colorectal cancer, HER2 as a target has also been focused in recent years.